See more : X1 Entertainment Group Inc. (XONE.CN) Income Statement Analysis – Financial Results
Complete financial analysis of Cardiovascular Systems, Inc. (CSII) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cardiovascular Systems, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Guangdong Redwall New Materials Co., Ltd. (002809.SZ) Income Statement Analysis – Financial Results
- Keystone Microtech Corporation (6683.TWO) Income Statement Analysis – Financial Results
- Aurora Acquisition Corp. (AURCU) Income Statement Analysis – Financial Results
- G-III Apparel Group, Ltd. (GIII) Income Statement Analysis – Financial Results
- Biofrontera Inc. (BFRIW) Income Statement Analysis – Financial Results
Cardiovascular Systems, Inc. (CSII)
About Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc., a medical technology company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products comprising catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. In addition, it offers guidewires, catheters, balloons, embolic protection system, and other OAS support products. Cardiovascular Systems, Inc. has a partnership with Chansu Vascular Technologies, LLC to develop novel peripheral and coronary everolimus drug-coated balloons. The company was formerly known as Shturman Cardiology Systems, Inc. and changed its name to Cardiovascular Systems, Inc. in January 2003. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in Saint Paul, Minnesota.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 236.22M | 258.97M | 236.55M | 248.02M | 217.04M | 204.91M | 178.18M | 181.54M | 136.61M | 103.90M | 82.49M | 78.78M | 64.83M | 56.46M | 58.57M | 15.99M | 441.00K | 834.00K | 726.00K | 0.00 |
| Cost of Revenue | 63.44M | 61.13M | 48.76M | 47.68M | 39.48M | 39.44M | 35.42M | 39.52M | 31.04M | 24.38M | 19.22M | 16.28M | 15.00M | 16.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 172.78M | 197.84M | 187.79M | 200.34M | 177.56M | 165.47M | 142.76M | 142.02M | 105.57M | 79.52M | 63.27M | 62.50M | 49.83M | 40.27M | 58.57M | 15.99M | 441.00K | 834.00K | 726.00K | 0.00 |
| Gross Profit Ratio | 73.14% | 76.39% | 79.39% | 80.78% | 81.81% | 80.75% | 80.12% | 78.23% | 77.28% | 76.53% | 76.71% | 79.34% | 76.86% | 71.32% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 36.72M | 41.06M | 43.36M | 33.46M | 26.76M | 22.91M | 25.93M | 30.98M | 21.07M | 15.22M | 11.37M | 8.94M | 10.28M | 14.68M | 43.31M | 38.30M | 29.18M | 16.28M | 0.00 | 2.52M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 167.70M | 148.57M | 144.10M | 162.54M | 143.68M | 117.99M | 86.72M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 170.53M | 167.50M | 169.97M | 167.70M | 148.57M | 144.10M | 162.54M | 143.68M | 117.99M | 86.72M | 66.37M | 62.37M | 62.45M | 59.82M | 13.02M | 12.19M | 5.33M | 2.99M | 0.00 | 1.28M |
| Other Expenses | 1.34M | 1.22M | 1.23M | 760.00K | -390.00K | -164.00K | 53.00K | -162.00K | -706.00K | -671.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 208.59M | 209.78M | 214.56M | 201.16M | 175.33M | 167.01M | 188.48M | 174.66M | 139.06M | 101.93M | 77.74M | 71.31M | 72.73M | 74.50M | 56.33M | 50.48M | 34.51M | 19.28M | 0.00 | 3.79M |
| Cost & Expenses | 272.03M | 270.91M | 263.32M | 248.84M | 214.81M | 206.45M | 223.90M | 214.18M | 170.10M | 126.32M | 96.96M | 87.59M | 87.73M | 90.69M | 56.33M | 50.48M | 34.51M | 19.28M | 0.00 | 3.79M |
| Interest Income | 817.00K | 499.00K | 1.74M | 2.44M | 1.33M | 383.00K | 0.00 | 0.00 | 0.00 | -1.62M | 5.00K | 12.00K | 402.00K | 3.38M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.63M | 1.74M | 1.97M | 1.68M | 1.72M | 500.00K | 0.00 | 23.00K | 1.03M | 1.35M | 2.32M | 1.42M | 1.44M | 2.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.34M | 1.22M | 1.23M | 3.45M | 3.93M | 4.14M | 3.92M | 2.32M | 1.37M | 973.00K | 872.00K | 716.00K | 600.00K | 470.00K | 2.25M | 683.00K | 1.29M | 1.30M | 0.00 | 0.00 |
| EBITDA | -34.46M | -10.72M | -25.54M | -825.00K | 2.23M | -1.54M | -35.35M | -32.64M | -33.49M | -22.42M | -14.47M | -8.81M | -22.33M | -35.07M | -963.00K | -39.07M | -32.78M | -16.68M | 726.00K | -3.79M |
| EBITDA Ratio | -14.59% | -4.14% | -10.80% | -0.33% | 1.03% | -0.75% | -19.84% | -17.98% | -24.51% | -21.58% | -17.54% | -11.18% | -34.44% | -62.12% | -1.64% | -244.37% | -7,431.97% | -1,999.76% | 100.00% | 0.00% |
| Operating Income | -35.81M | -11.93M | -26.77M | -825.00K | -1.70M | -1.54M | -56.08M | -32.64M | -33.49M | -22.42M | -14.47M | -8.81M | -22.90M | -34.23M | 2.24M | -34.49M | -34.07M | -18.44M | 726.00K | -3.79M |
| Operating Income Ratio | -15.16% | -4.61% | -11.32% | -0.33% | -0.78% | -0.75% | -31.47% | -17.98% | -24.51% | -21.58% | -17.54% | -11.18% | -35.32% | -60.63% | 3.82% | -215.75% | -7,725.17% | -2,211.27% | 100.00% | 0.00% |
| Total Other Income/Expenses | -817.00K | -1.24M | -233.00K | 760.00K | 3.54M | -164.00K | 53.00K | -185.00K | -1.80M | -1.62M | -2.32M | 0.00 | 28.00K | 1.31M | 5.45M | 5.26M | 399.00K | -797.00K | 0.00 | 0.00 |
| Income Before Tax | -36.62M | -13.17M | -27.01M | -65.00K | 1.84M | -1.71M | -56.02M | -32.82M | -35.29M | -24.04M | -15.44M | 0.00 | -22.87M | -32.93M | 7.69M | -29.24M | -33.67M | -19.24M | 0.00 | 0.00 |
| Income Before Tax Ratio | -15.50% | -5.09% | -11.42% | -0.03% | 0.85% | -0.83% | -31.44% | -18.08% | -25.83% | -23.14% | -18.72% | 0.00% | -35.28% | -58.31% | 13.13% | -182.86% | -7,634.69% | -2,306.83% | 0.00% | 0.00% |
| Income Tax Expense | 310.00K | 252.00K | 231.00K | 190.00K | 132.00K | 86.00K | 6.39M | -2.30M | -333.00K | 344.00K | 479.00K | 1.60M | 1.01M | -25.12M | -5.45M | -5.25M | 0.00 | 797.00K | 13.95M | 3.76M |
| Net Income | -36.93M | -13.42M | -27.24M | -255.00K | 1.71M | -1.79M | -56.02M | -32.82M | -35.29M | -24.04M | -16.79M | -11.13M | -23.90M | -9.11M | 7.69M | -29.25M | -33.67M | -19.24M | -13.95M | -3.76M |
| Net Income Ratio | -15.63% | -5.18% | -11.51% | -0.10% | 0.79% | -0.87% | -31.44% | -18.08% | -25.83% | -23.14% | -20.35% | -14.12% | -36.87% | -16.14% | 13.13% | -182.94% | -7,634.69% | -2,306.83% | -1,921.49% | 0.00% |
| EPS | -0.94 | -0.35 | -0.79 | -0.01 | 0.05 | -0.06 | -1.72 | -1.04 | -1.25 | -1.11 | -0.93 | -0.70 | -1.62 | -1.13 | 2.90 | -21.03 | -323.00 | -257.79 | -208.20 | -53.01 |
| EPS Diluted | -0.94 | -0.35 | -0.79 | -0.01 | 0.05 | -0.06 | -1.72 | -1.04 | -1.25 | -1.11 | -0.93 | -0.70 | -1.62 | -1.13 | 2.80 | -21.03 | -323.00 | -257.79 | -208.20 | -53.01 |
| Weighted Avg Shares Out | 39.23M | 38.83M | 34.28M | 33.54M | 33.15M | 32.37M | 32.54M | 31.55M | 28.30M | 21.69M | 18.04M | 15.92M | 14.75M | 8.07M | 2.67M | 1.39M | 104.24K | 74.63K | 67.00K | 70.97K |
| Weighted Avg Shares Out (Dil) | 39.23M | 38.83M | 34.28M | 33.54M | 33.61M | 32.37M | 32.54M | 31.55M | 28.30M | 21.69M | 18.04M | 15.92M | 14.75M | 8.07M | 2.77M | 1.39M | 104.24K | 74.63K | 67.00K | 70.97K |
Cardiovascular Systems, Inc. to Host Earnings Conference Call on November 3, 2022
ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) plans to announce its operating results for the quarter ended September 30, 2022 before the market opens on Thursday, November 3, 2022, and will host a conference call at 8:00 a.m....
Why Is Cardiovascular Systems (CSII) Down 18.9% Since Last Earnings Report?
Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock?
Cardiovascular Systems, Inc. Reports Fiscal 2022 Fourth Quarter and Full Year Financial Results
ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with vascular and coronary artery disease, today reported financial results for its fourth quarter and full year, ended...
Cardiovascular Systems, Inc. Reports Fiscal 2022 Fourth Quarter and Full Year Financial Results
ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with vascular and coronary artery disease, today reported financial results for its fourth quarter and full year, ended...
Cardiovascular Systems, Inc. Reports Fiscal 2022 Fourth Quarter and Full Year Financial Results
ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2022 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
A Debt-Free and Fairly Valued Medical Devices Company
LeMaitre Vascular Inc. ( LMAT , Financial) has been on a roll—it has generated robust financial results and metrics that produced a high GF Score. But the share price has been in a slump.
Cardiovascular Systems, Inc. to Release Fiscal 2022 Fourth Quarter Results on August 2, 2022
ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. to Release Fiscal 2022 Fourth Quarter Results on August 2, 2022
Cardiovascular Systems, Inc. to Release Fiscal 2022 Fourth Quarter Results on August 2, 2022
ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) will release fourth-quarter results the evening of August 2. In lieu of hosting a quarterly earnings conference call, CSI management will discuss fourth-quarter results at the beginning of its capital markets...
Cardiovascular Systems, Inc. (CSII) CEO Scott Ward on Q3 2022 Results - Earnings Call Transcript
Cardiovascular Systems, Inc. (NASDAQ:CSII ) Q3 2022 Earnings Conference Call May 5, 2022 9:00 AM ET Company Participants Jack Nielsen - Vice President, Investor Relations Scott Ward - Chairman, President, and Chief Executive Officer Jeff Points - Chief Financial Officer...
Cardiovascular Systems' (CSII) Q3 Earnings Top Estimates
Cardiovascular Systems' (CSII) third-quarter revenues declined year over year due to lower Coronary and peripheral revenues.
Source: https://incomestatements.info
Category: Stock Reports